Non-Statin Cholesterol Medications Beyond Ezetimibe and Fenofibrate

Introduction to Non-Statin Therapies

The American College of Cardiology recommends bile acid sequestrants, PCSK9 inhibitors, and niacin-based preparations as effective alternative options for patients requiring cholesterol-lowering therapy who cannot take statins, ezetimibe, or fenofibrate, offering different mechanisms of action and varying degrees of LDL-C reduction to address cardiovascular risk 1, 2

Bile acid sequestrants work by binding bile acids in the intestinal lumen, diverting them from enterohepatic circulation, which depletes the liver of bile and upregulates LDL receptor activity, with examples including cholestyramine, colestipol, and colesevelam 1, 2
Bile acid sequestrants typically reduce LDL-C by 18-25% as monotherapy, with good evidence from randomized controlled trials showing approximately 20% reduction in cardiovascular disease events in primary prevention 1, 3
Colesevelam has the added benefit of modestly improving glycemic control in patients with type 2 diabetes 2
Common side effects of bile acid sequestrants include gastrointestinal complaints and potential drug interactions, and they are contraindicated in patients with high triglyceride levels due to risk of severe hypertriglyceridemia 3, 4

PCSK9 inhibitors are powerful LDL-lowering drugs that reduce LDL-C by 40-65%, with examples including evolocumab and alirocumab, and strong evidence for cardiovascular risk reduction when added to statin therapy 1, 3
PCSK9 inhibitors are generally well-tolerated but long-term safety data continues to accumulate, and they are more expensive than other non-statin therapies, which may limit accessibility 3, 5

Niacin-based preparations are available as crystalline niacin or extended-release niacin, reducing LDL-C by 20-25% and also significantly lowering triglycerides and raising HDL-C, with approximately 20% reduction in cardiovascular disease events as monotherapy 1, 2, 6
Niacin-based preparations also lower lipoprotein(a) by up to 30%, which may provide additional cardiovascular benefit, but side effects include flushing, pruritus, gastrointestinal disturbances, and potential liver enzyme elevations 2, 6

Combining non-statin therapies may provide additive LDL-C lowering effects, and for patients at very high cardiovascular risk, combination therapy may be necessary to achieve target LDL-C levels 5, 7
Newer agents like bempedoic acid, lomitapide, or mipomersen may be considered for specific patient populations, such as those with homozygous familial hypercholesterolemia 1

The American College of Cardiology recommends a step-wise approach to non-statin therapy, starting with PCSK9 inhibitors for highest LDL-C reduction and demonstrated cardiovascular benefit, considering cost and insurance coverage limitations 1, 5, 7
Monitoring recommendations include assessing lipid levels 4-8 weeks after initiating therapy, monitoring for medication-specific adverse effects, and adjusting therapy based on LDL-C response and tolerability 3, 6, 7